Breaking News Instant updates and real-time market news.

STAR

iStar

$11.63 /

-0.17 (-1.44%)

07:31
11/03/20
11/03
07:31
11/03/20
07:31

iStar reports Q3 adjusted EPS 29c, consensus 5c

"As transaction activity in the real estate markets begins to increase, iStar is well positioned to continue delivering modern ground lease capital to customers across the country," said Jay Sugarman, Chairman and CEO. "With the unrealized gain on our investment in Safehold now well over $1 billion, we are focused on helping more market participants understand the significant intrinsic value of our platform and the large opportunity still ahead of us."

  • 03

    Nov

  • 17

    Nov

TODAY'S FREE FLY STORIES

Periodicals
NY Gov. asks Pfizer to directly sell COVID vaccine doses, Reuters reports » 17:19
01/18/21
01/18
17:19
01/18/21
17:19
PFE

Pfizer

$36.70 /

-0.05 (-0.14%)

New York Governor Andrew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$36.70 /

-0.05 (-0.14%)

PFE Pfizer
$36.70 /

-0.05 (-0.14%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
PFE Pfizer
$36.70 /

-0.05 (-0.14%)

PFE Pfizer
$36.70 /

-0.05 (-0.14%)

PFE Pfizer
$36.70 /

-0.05 (-0.14%)

PFE Pfizer
$36.70 /

-0.05 (-0.14%)

Conference/Events
First Majestic to host conference call » 16:24
01/18/21
01/18
16:24
01/18/21
16:24
AG

First Majestic

$11.82 /

-0.83 (-6.56%)

Management discusses 4Q…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AG First Majestic
$11.82 /

-0.83 (-6.56%)

AG First Majestic
$11.82 /

-0.83 (-6.56%)

01/11/21 National Bank
First Majestic price target raised to C$20 from C$18 at National Bank
10/22/20 National Bank
First Majestic price target lowered to C$18 from C$20 at National Bank
10/20/20 TD Securities
First Majestic upgraded to Buy from Hold at TD Securities
09/11/20 National Bank
First Majestic price target raised to C$20 from C$19 at National Bank
AG First Majestic
$11.82 /

-0.83 (-6.56%)

AG First Majestic
$11.82 /

-0.83 (-6.56%)

AG First Majestic
$11.82 /

-0.83 (-6.56%)

Hot Stocks
CommScope files patent infringement suit against SOLiD in Germany » 16:17
01/18/21
01/18
16:17
01/18/21
16:17
COMM

CommScope

$14.72 /

-0.22 (-1.47%)

CommScope filed an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
COMM CommScope
$14.72 /

-0.22 (-1.47%)

COMM CommScope
$14.72 /

-0.22 (-1.47%)

12/21/20
Fly Intel: Top five analyst downgrades
12/21/20 Citi
CommScope downgraded to Sell from Neutral at Citi
12/11/20
Fly Intel: Top five analyst upgrades
12/11/20 JPMorgan
CommScope upgraded to Overweight with $18 target at JPMorgan
COMM CommScope
$14.72 /

-0.22 (-1.47%)

COMM CommScope
$14.72 /

-0.22 (-1.47%)

COMM CommScope
$14.72 /

-0.22 (-1.47%)

Earnings
Fly Intel: What to watch in next round of big banks' earnings reports » 16:09
01/18/21
01/18
16:09
01/18/21
16:09
BAC

Bank of America

$33.02 /

-0.97 (-2.85%)

, GS

Goldman Sachs

$301.05 /

-6.95 (-2.26%)

, MS

Morgan Stanley

$75.22 /

-1.25 (-1.63%)

Goldman Sachs (GS) and…

Goldman Sachs (GS) and Bank of America (BAC) are scheduled to announce quarterly results on January 19, while Morgan Stanley (MS) is expected to report on January 20. What to watch for: 1. SELECT OPPORTUNITIES AMONG BANKS: Last week, Citi analyst Keith Horowitz upgraded Bank of America to Buy from Neutral with a price target of $37, up from $31. A steeper curve "should be more readily evident with lower premium am, in addition to securities yield lift," Horowitz told investors in a research note. The analyst sees select opportunities among the banks. Those banks that have outperformed this year aren't the banks that stand to benefit the most from a steeper curve, creating opportunities, he added. 2. POSITIVE EARNINGS SURPRISES: Earlier this month, Barclays analyst Jason Goldberg upgraded Morgan Stanley to Overweight from Equal Weight with a price target of $88, up from $60. The analyst told investors that he expects Morgan Stanley to continue to benefit from positive earnings surprises, "relatively more aggressive" capital returns and improving revenue durability. While trading comps will likely be tough in 2021, results should "remain elevated," while investment banking activity remains heightened, Goldberg contended. Citing similar reasons, the analyst also upgraded Goldman Sachs to Overweight from Equal Weight with a price target of $362, up from $270. 3. 1MDB SETTLEMENT: In a regulatory filing back in October, Goldman Sachs Group announced that it had reached settlements of governmental and regulatory investigations relating to 1Malaysia Development Berhad, or 1MDB, with the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the Board of Governors of the Federal Reserve System, the New York State Department of Financial Services, the U.K. Financial Conduct Authority, the U.K. Prudential Regulation Authority, the Singapore Attorney General's Chambers, the Singapore Commercial Affairs Department, the Monetary Authority of Singapore and the Hong Kong Securities and Futures Commission. Goldman Sachs agreed to enter into a three-year deferred prosecution agreement with the DOJ, in which a charge against the firm, one count of conspiracy to violate the Foreign Corrupt Practices Act of 1977, will be filed and later dismissed if the firm abides by the terms of the agreement. In addition, Group Inc.'s subsidiary in Malaysia, GS Malaysia, has agreed to plead guilty to one count of conspiracy to violate the FCPA. The company will pay total penalties, after crediting, of approximately $2.6B in connection with the settlements. A separate obligation to pay $606M in disgorgement has been credited and satisfied as a result of the firm's earlier settlement with the Government of Malaysia, in which the company paid a total of $2.5B, in addition to providing a $1.4B asset recovery guarantee. This brings the total payments in connection with governmental and regulatory settlements relating to 1MDB to an aggregate of approximately $5.1B. 4. SHARE REPURCHASES: Back in December, Goldman Sachs said in a statement that, "We are pleased that the results of the Federal Reserve's latest stress test demonstrate the resilience of the largest U.S. financial institutions in the midst of a devastating pandemic. Based on the results and guidance from the Federal Reserve, we intend to resume share repurchases next quarter. In the meantime, we will continue to serve our clients and help them navigate a challenging economic environment." During its last earnings conference call, Morgan Stanley had also said that it sees resuming buybacks in the first quarter 2021.

ShowHide Related Items >><<
BAC Bank of America
$33.02 /

-0.97 (-2.85%)

GS Goldman Sachs
$301.05 /

-6.95 (-2.26%)

MS Morgan Stanley
$75.22 /

-1.25 (-1.63%)

BAC Bank of America
$33.02 /

-0.97 (-2.85%)

01/11/21 Citi
Bank of America upgraded to Buy from Neutral at Citi
01/11/21 Citi
Bank of America upgraded to Buy from Neutral at Citi
01/11/21 Piper Sandler
Bank of America price target raised to $36 from $28 at Piper Sandler
01/06/21 Deutsche Bank
Bank of America price target raised to $35 from $30 at Deutsche Bank
GS Goldman Sachs
$301.05 /

-6.95 (-2.26%)

01/12/21 JMP Securities
Goldman Sachs price target raised to $320 from $285 at JMP Securities
01/11/21 Piper Sandler
Goldman Sachs price target raised to $325 from $270 at Piper Sandler
01/06/21 Deutsche Bank
Goldman Sachs price target raised to $290 from $230 at Deutsche Bank
01/05/21 Wells Fargo
Goldman Sachs shares to pass all-time high 'soon,' says Wells Fargo
MS Morgan Stanley
$75.22 /

-1.25 (-1.63%)

01/11/21 Piper Sandler
Morgan Stanley price target raised to $76 from $54 at Piper Sandler
01/06/21 Deutsche Bank
Morgan Stanley price target raised to $68 from $53 at Deutsche Bank
01/04/21
Fly Intel: Top five analyst upgrades
01/04/21 Barclays
Morgan Stanley upgraded to Overweight with $88 target at Barclays
BAC Bank of America
$33.02 /

-0.97 (-2.85%)

GS Goldman Sachs
$301.05 /

-6.95 (-2.26%)

MS Morgan Stanley
$75.22 /

-1.25 (-1.63%)

BAC Bank of America
$33.02 /

-0.97 (-2.85%)

GS Goldman Sachs
$301.05 /

-6.95 (-2.26%)

MS Morgan Stanley
$75.22 /

-1.25 (-1.63%)

BAC Bank of America
$33.02 /

-0.97 (-2.85%)

GS Goldman Sachs
$301.05 /

-6.95 (-2.26%)

MS Morgan Stanley
$75.22 /

-1.25 (-1.63%)

BAC Bank of America
$33.02 /

-0.97 (-2.85%)

GS Goldman Sachs
$301.05 /

-6.95 (-2.26%)

MS Morgan Stanley
$75.22 /

-1.25 (-1.63%)

Hot Stocks
Chart Industries announces transfer from Nasdaq to NYSE » 16:01
01/18/21
01/18
16:01
01/18/21
16:01
GTLS

Chart Industries

$134.48 /

-2.5 (-1.83%)

Chart Industries…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GTLS Chart Industries
$134.48 /

-2.5 (-1.83%)

GTLS Chart Industries
$134.48 /

-2.5 (-1.83%)

01/06/21 Northland
Chart Industries price target raised to $137 from $104 at Northland
12/31/20 Credit Suisse
Chart Industries price target raised to $128 from $109 at Credit Suisse
12/16/20 Lake Street
Chart Industries price target raised to $134 from $111 at Lake Street
12/16/20 Craig-Hallum
Chart Industries price target raised to $147 from $107 at Craig-Hallum
GTLS Chart Industries
$134.48 /

-2.5 (-1.83%)

GTLS Chart Industries
$134.48 /

-2.5 (-1.83%)

Periodicals
Tesla says Model Y deliveries in China have officially begun » 15:45
01/18/21
01/18
15:45
01/18/21
15:45
TSLA

Tesla

$826.55 /

-17.94 (-2.12%)

Tesla announced via…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSLA Tesla
$826.55 /

-17.94 (-2.12%)

TSLA Tesla
$826.55 /

-17.94 (-2.12%)

01/15/21 Wedbush
Tesla price target raised to $950 from $715 at Wedbush
01/13/21
Fly Intel: Top five analyst initiations
01/13/21 Edward Jones
Edward Jones starts Tesla at Hold, sees leadership balanced by competition
01/13/21 Edward Jones
Tesla initiated with a Hold at Edward Jones
TSLA Tesla
$826.55 /

-17.94 (-2.12%)

  • 14
    Feb
TSLA Tesla
$826.55 /

-17.94 (-2.12%)

TSLA Tesla
$826.55 /

-17.94 (-2.12%)

TSLA Tesla
$826.55 /

-17.94 (-2.12%)

Periodicals
Lumentum in advanced talks to acquire Coherent, WSJ reports » 15:42
01/18/21
01/18
15:42
01/18/21
15:42
COHR

Coherent

$151.92 /

-3.36 (-2.16%)

, LITE

Lumentum

$106.19 /

-0.03 (-0.03%)

Lumentum Holdings (LITE)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
COHR Coherent
$151.92 /

-3.36 (-2.16%)

LITE Lumentum
$106.19 /

-0.03 (-0.03%)

COHR Coherent
$151.92 /

-3.36 (-2.16%)

01/12/21 Barclays
Coherent downgraded to Underweight from Equal Weight at Barclays
11/12/20 Longbow
Coherent downgraded to Neutral ahead of transition year at Longbow
11/12/20 Longbow
Coherent downgraded to Neutral from Buy at Longbow
11/11/20
Fly Intel: Top five analyst downgrades
LITE Lumentum
$106.19 /

-0.03 (-0.03%)

01/12/21 MKM Partners
Lumentum price target raised to $138 from $120 at MKM Partners
01/12/21 Susquehanna
Susquehanna names top five M&A candidates in Semi space
01/11/21 B. Riley Securities
Lumentum price target raised to $123 from $101 at B. Riley Securities
12/15/20
Fly Intel: Top five analyst upgrades
COHR Coherent
$151.92 /

-3.36 (-2.16%)

LITE Lumentum
$106.19 /

-0.03 (-0.03%)

LITE Lumentum
$106.19 /

-0.03 (-0.03%)

LITE Lumentum
$106.19 /

-0.03 (-0.03%)

LITE Lumentum
$106.19 /

-0.03 (-0.03%)

Hot Stocks
Air Canada to resume Boeing 737 MAX commercial operations on Feb. 1 » 13:11
01/18/21
01/18
13:11
01/18/21
13:11
ACDVF

Air Canada

$0.00 /

+ (+0.00%)

, BA

Boeing

$204.29 /

-5.6 (-2.67%)

Air Canada (ACDVF) said…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BA Boeing
$204.29 /

-5.6 (-2.67%)

ACDVF Air Canada
$0.00 /

+ (+0.00%)

ACDVF Air Canada
$0.00 /

+ (+0.00%)

01/11/21 Cowen
Air Canada upgraded to Outperform from Market Perform at Cowen
01/08/21 BofA
Air Canada upgraded to Buy from Neutral at BofA
01/05/21 RBC Capital
Air Canada price target lowered to C$27 from C$30 at RBC Capital
01/04/21 Scotiabank
Air Canada price target lowered to C$29 from C$30 at Scotiabank
BA Boeing
$204.29 /

-5.6 (-2.67%)

01/04/21
Fly Intel: Top five analyst downgrades
01/04/21 Baird
Boeing elevated to Fresh Pick at Baird
01/04/21 Bernstein
Bernstein downgrades Boeing to Underperform on worsening 787 outlook
01/04/21 Bernstein
Boeing downgraded to Underperform from Market Perform at Bernstein
BA Boeing
$204.29 /

-5.6 (-2.67%)

BA Boeing
$204.29 /

-5.6 (-2.67%)

ACDVF Air Canada
$0.00 /

+ (+0.00%)

BA Boeing
$204.29 /

-5.6 (-2.67%)

BA Boeing
$204.29 /

-5.6 (-2.67%)

Initiation
Tesco reinstated with a Buy at Goldman Sachs » 13:09
01/18/21
01/18
13:09
01/18/21
13:09
TSCDY

Tesco

$0.00 /

+ (+0.00%)

Goldman Sachs analyst Rob…

Goldman Sachs analyst Rob Joyce reinstated coverage of Tesco with a Buy rating and 295 GBp price target. With the "broadest and cheapest" entry level pricing in the U.K., alongside the lowest cost to serve online orders, Tesco is well positioned to hold onto share gained from the discounters in 2020, while growing profits, Joyce tells investors in a research note.

ShowHide Related Items >><<
TSCDY Tesco
$0.00 /

+ (+0.00%)

TSCDY Tesco
$0.00 /

+ (+0.00%)

01/04/21 Barclays
Tesco reinstated with an Overweight at Barclays
01/04/21 Barclays
Tesco reinstated with an Overweight at Barclays
12/17/20 Morgan Stanley
Tesco price target raised to 287 GBp from 276 GBp at Morgan Stanley
10/23/20 Kepler Cheuvreux
Tesco downgraded to Hold from Buy at Kepler Cheuvreux
Hot Stocks
Biohaven's troriluzole did not differentiate from placebo in Alzheimer's trial » 13:06
01/18/21
01/18
13:06
01/18/21
13:06
BHVN

Biohaven Pharmaceutical

$84.76 /

-7.065 (-7.69%)

Biohaven Pharmaceutical…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$84.76 /

-7.065 (-7.69%)

BHVN Biohaven Pharmaceutical
$84.76 /

-7.065 (-7.69%)

12/29/20 Cantor Fitzgerald
Biohaven price target raised to $115 from $109 at Cantor Fitzgerald
12/23/20 Piper Sandler
Piper 'comfortable' owning Biohaven shares into Alzheimer's readout
12/15/20 H.C. Wainwright
Biohaven Pharmaceutical initiated with a Buy at H.C. Wainwright
12/07/20 SVB Leerink
Biohaven Pharmaceutical price target raised to $120 from $85 at SVB Leerink
BHVN Biohaven Pharmaceutical
$84.76 /

-7.065 (-7.69%)

  • 29
    Jan
Hot Stocks
Granite announces $20M contact by California Department of Transportation » 13:02
01/18/21
01/18
13:02
01/18/21
13:02
GVA

Granite

$33.21 /

-0.7 (-2.06%)

Granite announced that it…

Granite announced that it has been awarded a $20M contract by the California Department of Transportation for the State Route 46 4-Lane Widening Project in Lost Hills, California. The contract is anticipated to be included in Granite's first quarter 2021 backlog. The project widens State Route 46 from a two-lane to a four-lane highway between post miles 29.7 and 31.9 in Kern County. Scope of work includes the construction of two new lanes, a bridge over the California Aqueduct, a high-intensity activated crosswalk beacon at the State Route 46/Bruning Avenue intersection, a large drainage basin on the west side of Lost Hills Road, as well as curb, gutter, and crosswalks throughout the town of Lost Hills.

ShowHide Related Items >><<
GVA Granite
$33.21 /

-0.7 (-2.06%)

GVA Granite
$33.21 /

-0.7 (-2.06%)

06/25/20 DA Davidson
Granite Construction price target lowered to $17 from $30 at DA Davidson
GVA Granite
$33.21 /

-0.7 (-2.06%)

Hot Stocks
Equinox announces positive drill results from Piaba Underground target » 13:00
01/18/21
01/18
13:00
01/18/21
13:00
EQX

Equinox Gold

$10.03 /

-0.455 (-4.34%)

Equinox Gold announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EQX Equinox Gold
$10.03 /

-0.455 (-4.34%)

EQX Equinox Gold
$10.03 /

-0.455 (-4.34%)

01/12/21 BMO Capital
Equinox Gold price target raised to C$22.50 from C$22 at BMO Capital
01/11/21 National Bank
Equinox Gold price target lowered to C$17 from C$18 at National Bank
01/11/21 Scotiabank
Equinox Gold price target lowered to C$18.25 from C$19.25 at Scotiabank
12/21/20 BMO Capital
Equinox Gold price target raised to C$22 from C$21.50 at BMO Capital
EQX Equinox Gold
$10.03 /

-0.455 (-4.34%)

Hot Stocks
AstraZeneca, Daiichi announce FDA approval of Enhertu for gastric cancer » 12:58
01/18/21
01/18
12:58
01/18/21
12:58
AZN

AstraZeneca

$51.35 /

+0.05 (+0.10%)

AstraZeneca and Daiichi…

AstraZeneca and Daiichi Sankyo said Enhertu has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. The approval by the Food and Drug Administration was based on the positive results from the randomized DESTINY-Gastric01 Phase II trial conducted in Japan and South Korea. Enhertu is approved with Boxed Warnings for interstitial lung disease or pneumonitis and embryo-fetal toxicity. This is the second indication approved for Enhertu in the U.S. following the accelerated approval for adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting based on the DESTINY-Breast01 trial.

ShowHide Related Items >><<
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

Hot Stocks
Quest enters agreement with CDC for genomic sequencing of Covid variants » 12:56
01/18/21
01/18
12:56
01/18/21
12:56
DGX

Quest Diagnostics

$124.35 /

-0.56 (-0.45%)

Quest Diagnostics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
10/26/20 Mizuho
Quest Diagnostics price target raised to $149 from $144 at Mizuho
10/21/20 Argus
Quest Diagnostics upgraded to Buy from Hold at Argus
DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

Hot Stocks
Reliance Steel promotes Karla Lewis to President, names Arthur Ajemyan CFO » 12:46
01/18/21
01/18
12:46
01/18/21
12:46
RS

Reliance Steel

$127.66 /

-4.16 (-3.16%)

Reliance Steel &…

Reliance Steel & Aluminum announced that Karla Lewis has been promoted to President and appointed to the company's board. Prior to being named President, Lewis served as Senior Executive Vice President and Chief Financial Officer. In concert with Lewis' promotion, Reliance also announced the promotion of Arthur Ajemyan to Vice President, Chief Financial Officer effective January 15. Ajemyan became Vice President, Corporate Controller in May 2014.

ShowHide Related Items >><<
RS Reliance Steel
$127.66 /

-4.16 (-3.16%)

RS Reliance Steel
$127.66 /

-4.16 (-3.16%)

01/08/21 Deutsche Bank
Reliance Steel downgraded to Hold from Buy at Deutsche Bank
01/08/21 Deutsche Bank
Reliance Steel downgraded to Hold from Buy at Deutsche Bank
10/23/20
Fly Intel: Top five analyst upgrades
10/23/20 BofA
Reliance Steel upgraded to Buy from Neutral at BofA
RS Reliance Steel
$127.66 /

-4.16 (-3.16%)

Hot Stocks
Zomedica regained compliance with NYSE American's listing standards » 12:44
01/18/21
01/18
12:44
01/18/21
12:44
ZOM

Zomedica

$0.98 /

-0.0298 (-2.97%)

Zomedica said in a letter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZOM Zomedica
$0.98 /

-0.0298 (-2.97%)

ZOM Zomedica
$0.98 /

-0.0298 (-2.97%)

06/17/20 H.C. Wainwright
Zomedica price target lowered to 50c from 65c at H.C. Wainwright
  • 02
    Jul
Hot Stocks
Tronox 'very optimistic' about short-, long-term potential for TiO2 » 12:40
01/18/21
01/18
12:40
01/18/21
12:40
TROX

Tronox

$14.68 /

-0.375 (-2.49%)

The company said,…

The company said, "We remain confident that our vertical integration strategy will continue to provide a competitive advantage, allowing Tronox to deliver reliable, safe, quality, low-cost, sustainable tons to our customers while outperforming our TiO2 peers. The TiO2 business continues to benefit from the global industry recovery in 2021. With the current momentum, we are very optimistic about the short-, medium-, and long-term potential for both TiO2 and Tronox as the leading integrated supplier in the industry."

ShowHide Related Items >><<
TROX Tronox
$14.68 /

-0.375 (-2.49%)

TROX Tronox
$14.68 /

-0.375 (-2.49%)

12/28/20 Alembic Global
Dow Inc., Olin, Tronox named among 2021 chemical top picks at Alembic Global
06/05/20 JPMorgan
JPMorgan calls Tronox 'the forgotten cyclical'
05/08/20 Truist
Tronox price target lowered to $12 from $20 at SunTrust
TROX Tronox
$14.68 /

-0.375 (-2.49%)

Earnings
Tronox sees Q4 revenue $783M, consensus $696.29M » 12:39
01/18/21
01/18
12:39
01/18/21
12:39
TROX

Tronox

$14.68 /

-0.375 (-2.49%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TROX Tronox
$14.68 /

-0.375 (-2.49%)

TROX Tronox
$14.68 /

-0.375 (-2.49%)

12/28/20 Alembic Global
Dow Inc., Olin, Tronox named among 2021 chemical top picks at Alembic Global
06/05/20 JPMorgan
JPMorgan calls Tronox 'the forgotten cyclical'
05/08/20 Truist
Tronox price target lowered to $12 from $20 at SunTrust
Hot Stocks
Tronox intends to increase annualized dividend to 32c from 28c » 12:38
01/18/21
01/18
12:38
01/18/21
12:38
TROX

Tronox

$14.68 /

-0.375 (-2.49%)

The company said,…

The company said, "The Board intends to increase our annualized dividend to $0.32 per share from $0.28 per share, which equates to a 14 percent increase effective with the regular first quarter 2021 dividend. This reflects the confidence we have in the trajectory of the recovery in the sector and in our differentiated business model and is consistent with our previously stated goal to increase dividends as business conditions permit."

ShowHide Related Items >><<
TROX Tronox
$14.68 /

-0.375 (-2.49%)

TROX Tronox
$14.68 /

-0.375 (-2.49%)

12/28/20 Alembic Global
Dow Inc., Olin, Tronox named among 2021 chemical top picks at Alembic Global
06/05/20 JPMorgan
JPMorgan calls Tronox 'the forgotten cyclical'
05/08/20 Truist
Tronox price target lowered to $12 from $20 at SunTrust
Hot Stocks
Tronox announces termination of TiZir Titanium and Iron acquisition agreement » 12:37
01/18/21
01/18
12:37
01/18/21
12:37
TROX

Tronox

$14.68 /

-0.375 (-2.49%)

Tronox Holdings released…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TROX Tronox
$14.68 /

-0.375 (-2.49%)

TROX Tronox
$14.68 /

-0.375 (-2.49%)

12/28/20 Alembic Global
Dow Inc., Olin, Tronox named among 2021 chemical top picks at Alembic Global
06/05/20 JPMorgan
JPMorgan calls Tronox 'the forgotten cyclical'
05/08/20 Truist
Tronox price target lowered to $12 from $20 at SunTrust
Hot Stocks
Grifols to begin clinical trial in Spain for new COVID-19 drug » 12:34
01/18/21
01/18
12:34
01/18/21
12:34
GRFS

Grifols

$19.10 /

-0.05 (-0.26%)

Grifols announced it will…

Grifols announced it will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease. "The new drug would provide immediate post-exposure protection against the virus and would be especially useful as a complement to the vaccine in the early phase after vaccination. In addition, it could protect the elderly and healthcare workers as well as immunocompromised patients for whom vaccination isn't recommended. It could also help contain outbreaks in places where the vaccination hasn't begun or is still underway," the company said. Grifols expects this clinical trial, led by the researchers Oriol Mitja and Bonaventura Clotet, from Germans Trias i Pujol Hospital in Barcelona, to begin in February 2021, with the possibility of results in the spring.

ShowHide Related Items >><<
GRFS Grifols
$19.10 /

-0.05 (-0.26%)

GRFS Grifols
$19.10 /

-0.05 (-0.26%)

01/13/21 Morgan Stanley
Grifols price target lowered to EUR 31 from EUR 32 at Morgan Stanley
12/09/20 Morgan Stanley
Grifols price target raised to EUR 32 from EUR 31 at Morgan Stanley
11/06/20 Morgan Stanley
Grifols price target raised to EUR 31 from EUR 30 at Morgan Stanley
10/30/20 Berenberg
Grifols price target lowered to EUR 24.50 from EUR 25.30 at Berenberg
GRFS Grifols
$19.10 /

-0.05 (-0.26%)

GRFS Grifols
$19.10 /

-0.05 (-0.26%)

Hot Stocks
New Oriental Education names CFO Zhihui Yang Executive President » 12:31
01/18/21
01/18
12:31
01/18/21
12:31
EDU

New Oriental Education

$172.75 /

-3.255 (-1.85%)

New Oriental Education…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EDU New Oriental Education
$172.75 /

-3.255 (-1.85%)

01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
12/28/20 Citi
Citi keeps 'long-term positive stance' on New Oriental Education
11/30/20 CLSA
New Oriental Education weakness a buying opportunity, says CLSA
11/25/20 Morgan Stanley
OneSmart downgraded to Equal Weight on margin pressure at Morgan Stanley
EDU New Oriental Education
$172.75 /

-3.255 (-1.85%)

EDU New Oriental Education
$172.75 /

-3.255 (-1.85%)

Hot Stocks
Partner says lawsuit against subsidiary recognized as class action » 12:30
01/18/21
01/18
12:30
01/18/21
12:30
PTNR

Partner Communications

$5.06 /

-0.1 (-1.94%)

Partner Communications…

Partner Communications announces that on January 15, 2021, the Lod-Central District Court ruled to recognize the lawsuit against a subsidiary of the company, 012 Smile Telecom, as a class action, which concerns the claim that 012 Smile sold to its customers data browsing packages at a specified speed, which is not possible for them to achieve since the infrastructure does not support this speed. A similar decision was also given in a lawsuit against a competing company. "The causes of action for which the motion was approved are, among others, misleading acts and breach of contract," the company said in a statement. 012 Smile is studying the decision and will treat it in accordance with the dates set by law, it added.

ShowHide Related Items >><<
PTNR Partner Communications
$5.06 /

-0.1 (-1.94%)

PTNR Partner Communications
$5.06 /

-0.1 (-1.94%)

12/02/20 Barclays
Partner Communications price target raised to ILS 1,900 at Barclays
Hot Stocks
Guardant Health announces partnership with Vall d'Hebron Institute of Oncology » 12:29
01/18/21
01/18
12:29
01/18/21
12:29
GH

Guardant Health

$159.27 /

+1.77 (+1.12%)

Guardant Health and Vall…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GH Guardant Health
$159.27 /

+1.77 (+1.12%)

GH Guardant Health
$159.27 /

+1.77 (+1.12%)

01/14/21 Canaccord
Natera price target raised to $125 from $112 at Canaccord
01/12/21 Canaccord
Guardant Health price target raised to $170 from $145 at Canaccord
01/11/21
Fly Intel: Top five analyst initiations
01/11/21 Stifel
Guardant Health initiated with a Buy at Stifel
GH Guardant Health
$159.27 /

+1.77 (+1.12%)

  • 07
    Oct
  • 02
    Jun
GH Guardant Health
$159.27 /

+1.77 (+1.12%)

Hot Stocks
Calliditas says Phase 1 setanaxib trial shows favorable pharmacokinetic profile » 12:28
01/18/21
01/18
12:28
01/18/21
12:28
CALT

Calliditas Therapeutics

$30.55 /

-0.61 (-1.96%)

Genkyotex SA, a…

Genkyotex SA, a subsidiary of Calliditas Therapeutics, announced "positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex's lead asset." The Phase 1 study demonstrated that setanaxib is well tolerated at the doses tested, with no safety signal or dose-limiting toxicity being identified, the company said. The results provide an opportunity for the company to pursue a pivotal Phase 2/3 clinical trial in patients with primary biliary cholangitis (PBC), based on interactions with the FDA, it added. The study assessed the safety and pharmacokinetics of oral setanaxib at selected doses in 46 healthy adult male and female subjects. The trial consisted of a single ascending dose part and a multiple ascending dose part with dosing up to 1600mg/day. Previously, doses of up to 800 mg/day were evaluated in a 24-week Phase 2 trial in PBC patients. In that trial, setanaxib dosed at 800 mg/day achieved reductions in markers of cholestasis, including alkaline phosphatase, and in multiple non-invasive markers of liver fibrogenesis, including liver stiffness and PRO-C3 and C3M. Significant improvement in fatigue was also achieved. All doses tested in that trial were well-tolerated, with no safety signal compared to placebo. Calliditas controls 86.2% of the share capital and total number of votes of Genkyotex.

ShowHide Related Items >><<
CALT Calliditas Therapeutics
$30.55 /

-0.61 (-1.96%)

CALT Calliditas Therapeutics
$30.55 /

-0.61 (-1.96%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
  • 05
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.